2013-02-25 23:41:30 -
BURNABY, BRITISH COLUMBIA -- (Marketwire) -- 02/25/13 -- LED Medical Diagnostics Inc. (TSX VENTURE:LMD)(FRANKFURT:LME) ("LED Medical", "the Company"), a developer of tissue visualization detection technologies for the medical industry, is pleased to announce the appointment of Wayne Rees as Senior Vice President of its wholly-owned subsidiary, LED Dental Inc. ("LED Dental").
Mr. Rees is a 30-year veteran in the dental and medical products industry, and previously held several key positions at LED Dental, including most recently running its Canadian sales and marketing operations. Prior to joining LED Dental, Mr. Rees co-founded a dental company that was ultimately sold to PracticeWorks, Inc., which in turn was purchased by Eastman Kodak for $468 million in 2003. Mr. Rees subsequently served as Vice President of PracticeWorks Canada, which was renamed Kodak Dental.
Mr. Rees' primary responsibility will be to manage LED Dental's internal operations and to oversee its relationship with Den-Mat Holdings, LLC, which became the exclusive worldwide distributor for its VELscope Vx® Enhanced Oral Assessment System late in 2012.
"Wayne has an impressive history of success within the dental industry and is ideally suited for the role of Senior Vice President," states Peter Whitehead, founder and CEO of parent company, LED Medical Diagnostics Inc. "Wayne has an unparalleled understanding of how our state-of-the-art VELscope Vx® technology can benefit dental practices and patients alike, and he will ensure that LED Dental achieves its considerable potential."
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LED" as well as the Frankfurt Stock Exchange under the symbol "LME".
Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope Vx® Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope Vx® devices are now used to conduct more screenings for oral cancer and other oral tissue abnormalities than any other adjunctive device. To date, there have been more than 13,000 VELscope Vx® systems installed globally and they have been used to perform more than 25 million oral screenings. For more information, visit www.leddental.com : www.leddental.com/
Forward Looking Information
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Several factors could cause actual events or results to differ materially from those suggested by these forward-looking statements. Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2011. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
LED Medical Diagnostics Inc.
Mark Komonoski, Investor Relations
(403) 255-8483 or Toll-Free: (877) 255-8483
Cell: (403) 470-8384 firstname.lastname@example.org
/ Skype: mkomonoski
at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid= .. width="1" height="1" alt=" " border="0" />